A dual GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (weight management). Trials reported notably large reductions in body weight.
Mechanism under study
Simultaneously activates the GIP and GLP-1 receptors, combining two incretin pathways to improve insulin secretion, reduce appetite, and slow gastric emptying.
Research-reported dosing
Approved regimens titrate from 2.5 mg weekly up to 15 mg weekly over months. Slow titration is central to tolerability.
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
A 2.5 mg dose ≈ 50 units (50 mcg per unit).
Open this mix in the calculator →Source research-grade Tirzepatide ↗Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Tirzepatide comparisons
Tirzepatide FAQ
What is Tirzepatide?
A dual GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (weight management). Trials reported notably large reductions in body weight.
What is the half-life of Tirzepatide?
Approximately 5 days, supporting once-weekly clinical dosing.
What is the research-reported dosing for Tirzepatide?
Approved regimens titrate from 2.5 mg weekly up to 15 mg weekly over months. Slow titration is central to tolerability.
How is Tirzepatide reconstituted?
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
Is Tirzepatide FDA-approved?
Tirzepatide has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.
References
Guides featuring Tirzepatide
Related peptides
Semaglutide
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist, FDA-approved for type-2 diabetes and chronic weight management under brand names Ozempic, Wegovy, and Rybelsus. One of the most-studied incretin peptides.
Retatrutide
Triple GIP / GLP-1 / glucagon receptor agonist
An investigational 'triple agonist' targeting the GIP, GLP-1, and glucagon receptors. Phase-2 trials reported among the largest weight reductions seen for an incretin agent. Not approved.
MOTS-c
Mitochondrial-derived peptide
A mitochondrial-derived peptide studied as a metabolic regulator and exercise-mimetic in preclinical models, and of interest in aging and insulin-sensitivity research.